Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
JBIO · against 488 other Healthcare companies of similar size
Ranked #331 of 489 · scores higher than 10% of peers
Bars: peers in each 10-point band of the valuation score159 peers with a valuation score of 0–9, including JBIO · Click a bar to see the companies
Mainly because of its EBITDA yield, free cash flow yield and earnings yield, which are weaker than most Healthcare peers.
| Metric | JBIO | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 477 reported | -7.3% | 1.2% | 23% | 30% | |
| EBITDA yieldHigher is better · 495 reported | -35.3% | 4.2% | 4% | 50% | |
| Free cash flow yieldHigher is better · 211 reported | -13.3% | -2.6% | 21% | 20% | |
| Book yieldHigher is better · 486 reported | 47.5% | 41.7% | 57% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 12.9B HKD (≈$1.7B) | 99 | 83 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 226.3B JPY (≈$1.5B) | 99 | 77 | |
| 1 | 14.8B MXN (≈$800M) | 99 | 61 | |
| 331 | 552M USD | 8 | 39 | |
| 331 | 1.1B USD | 8 | 26 | |
| 331 | 1.2B USD | 8 | 6 | |
| 331 | 1.1B USD | 8 | 50 | |
| 331 | 927M USD | 8 | 41 | |
| 331 | 820M USD | 8 | 41 | |
| 331 | 1.7B USD | 8 | 46 | |
| 331 | 879M USD | 8 | 36 | |
| 331 | 1.3B USD | 8 | 39 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score